Aptinyx Inc (APTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aptinyx Inc (APTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8164
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aptinyx Inc. (Aptinyx), formerly Enarex Inc, is a clinical-stage biopharmaceutical company that discovers and develops novel therapies for the treatment of neurological disorders. The company’s proprietary chemistry platform helps develop a pipeline of small-molecule modulators of N-methyl-D-aspartate (NMDA) receptors and improves synaptic plasticity. Many NMDA receptor modulators are under clinical development as differentiated therapies for depression, and they possess efficacy and safety with the potential to treat various neurologic disorders. The company’s pipeline products include NYX-2925, which is under clinical development as a therapy for neuropathic pain; NYX-783, for post-traumatic stress disorder (PTSD); and NYX-458, for the treatment of cognitive impairment associated with Parkinson’s disease. Aptinyx is headquartered in Evanston, Illinois, the US.

Aptinyx Inc (APTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptinyx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aptinyx Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Aptinyx Raises USD70 Million in Series B Financing 11
Aptinyx Raises USD65 Million in Series A Venture Financing 13
Aptinyx Raises Funds through Seed Financing 15
Partnerships 16
Allergan Exercises Option to Acquire AGN-241751 from Aptinyx 16
Aptinyx to Enter into Research Partnership with Allergan 17
Equity Offering 18
Aptinyx Raises USD117.8 Million in IPO of Shares 18
Aptinyx Spin Off from Naurex 20
Aptinyx Inc – Key Competitors 21
Aptinyx Inc – Key Employees 22
Aptinyx Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 14, 2018: Aptinyx announces second quarter 2018 financial results 24
Corporate Communications 26
May 17, 2018: Aptinyx Appoints Robert Hombach to Board of Directors 26
May 03, 2018: Aptinyx Promotes David Houck to Chief Development Officer 27
Feb 13, 2018: Aptinyx Names Ashish Khanna As Chief Financial Officer and Chief Business Officer 28
Dec 07, 2017: Aptinyx Bolsters Executive Leadership Team With Appointment of Andy Kidd as Chief Commercial Officer 29
Clinical Trials 30
Mar 15, 2018: Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson’s Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Aptinyx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptinyx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptinyx Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aptinyx Raises USD70 Million in Series B Financing 11
Aptinyx Raises USD65 Million in Series A Venture Financing 13
Aptinyx Raises Funds through Seed Financing 15
Allergan Exercises Option to Acquire AGN-241751 from Aptinyx 16
Aptinyx to Enter into Research Partnership with Allergan 17
Aptinyx Raises USD117.8 Million in IPO of Shares 18
Aptinyx Spin Off from Naurex 20
Aptinyx Inc, Key Competitors 21
Aptinyx Inc, Key Employees 22
Aptinyx Inc, Other Locations 23

List of Figures
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Aptinyx Inc (APTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tecpetrol SA:企業の戦略的SWOT分析
    Tecpetrol SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Intercept Pharmaceuticals Inc (ICPT):企業の財務・戦略的SWOT分析
    Intercept Pharmaceuticals Inc (ICPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • TDC AS:企業の戦略的SWOT分析
    TDC AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Reins International Inc.:企業の戦略・SWOT・財務情報
    Reins International Inc. - Strategy, SWOT and Corporate Finance Report Summary Reins International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Triple-S Management Corp (GTS):企業の財務・戦略的SWOT分析
    Triple-S Management Corp (GTS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Sihuan Pharmaceutical Holdings Group Ltd (460):企業の財務・戦略的SWOT分析
    Summary Sihuan Pharmaceutical Holdings Group Ltd (Sihuan Pharmaceutical) is a pharmaceutical company that develops, manufactures and markets prescription drugs. The company offers products in the therapeutic areas of cardio-cerebral vascular system, central nervous system, metabolism, oncology and a …
  • Aptevo Therapeutics Inc (APVO):製薬・医療:M&Aディール及び事業提携情報
    Summary Aptevo Therapeutics Inc (Aptevo), a subsidiary of Emergent Biosolutions Inc, is a biotechnology company that develops and commercializes oncology and hematology therapeutics. The company’s only marketed product Ixinity that is indicated to replace the missing clotting factor IX in adults and …
  • Pendopharm-製薬・医療分野:企業M&A・提携分析
    Summary PendoPharm is a healthcare company that offers production and commercialization of a wide range of drugs. The company’s products comprise spans prescription drugs, over-the-counter and behind-the-counter products. Its prescription products offers drugs for therapeutic areas of gastroenterolo …
  • GeNeuro SA (GNRO):製薬・医療:M&Aディール及び事業提携情報
    Summary GeNeuro SA (GeNeuro) is a clinical stage pharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. The company provides treatments against inflammatory and degenerative disorders associated with endogenous retroviruses. GeNeuro develops therap …
  • Echelon Corporation (ELON):企業の財務・戦略的SWOT分析
    Echelon Corporation (ELON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Stantec Inc:企業のM&A・事業提携・投資動向
    Stantec Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Stantec Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Leica Microsystems GmbH:企業のM&A・事業提携・投資動向
    Leica Microsystems GmbH - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Leica Microsystems GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Episurf Medical AB (EPIS B):医療機器:M&Aディール及び事業提携情報
    Summary Episurf Medical AB (Episurf Medical), formerly Diamorph Medtech AB is a medical technology company that provides patient-specific treatments of painful joint injuries. The company offers diagnosis and design of implants and surgical instruments. Its products include Episealer Femoral Twin, E …
  • Cboe Global Markets, Inc (CBOE):企業の財務・戦略的SWOT分析
    Cboe Global Markets, Inc (CBOE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Emcure Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Emcure Pharmaceuticals Ltd (Emcure) develops, manufactures and markets a range of pharmaceutical products worldwide. The company specializes in the development and manufacture of differentiated pharmaceutical products. It also manufactures active pharmaceutical ingredients (APIs) primarily f …
  • Aero Components Inc.:企業の戦略・SWOT・財務情報
    Aero Components Inc. - Strategy, SWOT and Corporate Finance Report Summary Aero Components Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Revolution Medicines Inc-製薬・医療分野:企業M&A・提携分析
    Summary Revolution Medicines Inc (Revolution Medicines) is a drug discovery company with focus on the development of therapies for cancer. The company’s programs include SHP2 Program and mTOR Program. Its REVBLOCKS platform, an integrated suite of modular synthesis methodologies, facilitates the pro …
  • Syneron Medical Ltd:企業の戦略的SWOT分析
    Syneron Medical Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • China Aviation Oil (Singapore) Corp Ltd (G92)
    China Aviation Oil (Singapore) Corp Ltd (G92) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Strategic Energy Resources Ltd (SER):企業の財務・戦略的SWOT分析
    Summary Strategic Energy Resources Ltd (SER) is a mining company. It explores, develops, and produces mineral properties. The company product offerings include gold, copper and mineral sands. SER holds in Saxby gold project, Myall Creek project, Billa Kalina Copper-Gold Project and East Tennant copp …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆